India · Delayed Price · Currency is INR Gland Pharma Statistics
Total Valuation
Gland Pharma has a market cap or net worth of INR 317.80 billion. The enterprise value is 291.41 billion.
| Market Cap | 317.80B |
| Enterprise Value | 291.41B |
Important Dates
The next estimated earnings date is Monday, November 3, 2025.
| Earnings Date | Nov 3, 2025 |
| Ex-Dividend Date | Aug 14, 2025 |
Share Statistics
| Current Share Class | 164.76M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +0.03% |
| Shares Change (QoQ) | -0.03% |
| Owned by Insiders (%) | 0.01% |
| Owned by Institutions (%) | 37.09% |
| Float | 73.18M |
Valuation Ratios
The trailing PE ratio is 41.26.
| PE Ratio | 41.26 |
| Forward PE | n/a |
| PS Ratio | 5.56 |
| PB Ratio | 3.47 |
| P/TBV Ratio | 3.61 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 37.83 |
| EV / Sales | 5.09 |
| EV / EBITDA | 21.54 |
| EV / EBIT | 30.15 |
| EV / FCF | n/a |
Financial Position
| Current Ratio | n/a |
| Quick Ratio | n/a |
| Debt / Equity | 0.03 |
| Debt / EBITDA | 0.23 |
| Debt / FCF | n/a |
| Interest Coverage | 22.33 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | 6.51% |
| Return on Capital Employed (ROCE) | n/a |
| Revenue Per Employee | 13.15M |
| Profits Per Employee | 1.77M |
| Employee Count | 4,351 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Gland Pharma has paid 3.87 billion in taxes.
| Income Tax | 3.87B |
| Effective Tax Rate | 33.44% |
Stock Price Statistics
The stock price has increased by +16.41% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +16.41% |
| 50-Day Moving Average | 1,942.47 |
| 200-Day Moving Average | 1,722.44 |
| Relative Strength Index (RSI) | 48.36 |
| Average Volume (20 Days) | 6,345 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Gland Pharma had revenue of INR 57.20 billion and earned 7.70 billion in profits. Earnings per share was 46.75.
| Revenue | 57.20B |
| Gross Profit | 33.02B |
| Operating Income | 9.66B |
| Pretax Income | 11.57B |
| Net Income | 7.70B |
| EBITDA | 13.34B |
| EBIT | 9.66B |
| Earnings Per Share (EPS) | 46.75 |
Balance Sheet
The company has 29.52 billion in cash and 3.14 billion in debt, giving a net cash position of 26.38 billion.
| Cash & Cash Equivalents | 29.52B |
| Total Debt | 3.14B |
| Net Cash | 26.38B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 91.51B |
| Book Value Per Share | 555.41 |
| Working Capital | n/a |
Cash Flow
| Operating Cash Flow | n/a |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 57.73%, with operating and profit margins of 16.89% and 13.46%.
| Gross Margin | 57.73% |
| Operating Margin | 16.89% |
| Pretax Margin | 20.23% |
| Profit Margin | 13.46% |
| EBITDA Margin | 23.32% |
| EBIT Margin | 16.89% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 18.00, which amounts to a dividend yield of 0.94%.
| Dividend Per Share | 18.00 |
| Dividend Yield | 0.94% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | 1 |
| Payout Ratio | n/a |
| Buyback Yield | -0.03% |
| Shareholder Yield | 0.91% |
| Earnings Yield | 2.42% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |